G01N 2333/5755
Neuropeptide y
Official title: Neuropeptide Y
G01N2333/5755 (Neuropeptide y) appears on 11 US grants and 17 published applications in this corpus.
Search patents in G01N- Granted patents
- 11
- Published applications
- 17
- Assignees
- 18
- Inventors
- 53
- Latest grant
- 6 Feb 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 0 |
| 2003 | 1 | 2 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 2 |
| 2014 | 0 | 2 |
| 2015 | 1 | 1 |
| 2016 | 1 | 1 |
| 2017 | 0 | 2 |
| 2018 | 1 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biosensor device and assembly methods6 Feb 2024US 11,891,652 B2Queen Mary University of London
- Method using an Y1 receptor activator for treating an anticancer agent-induced nephrotoxic injury4 Dec 2018US 10,143,727 B2Kyungpook National University Industry-Academic Cooperation Foundation
- Mass spectrometric methods for quantifying NPY 1-36 and NPY 3-3623 Feb 2016US 9,269,550 B2Georgetown University
- Neuropeptide Q as modulator of GPCR GALR2 and uses thereof16 Jun 2015US 9,057,726 B2Actelion Pharmaceuticals Ltd.
- Human performance biomarker binding peptides for neuropeptide Y and methods of using the same5 Nov 2013US 8,575,069 B1The United States of America as represented by the Secretary of the Air Force
- Biomarker for diagnosis, prognosis, assessment and therapy stratification28 May 2026US 2026/0147005 A1The University of Melbourne
- Non-Transgenic Functional Rescue of Neuropeptides1 Dec 2022US 2022/0380430 A1Worcester Polytechnic Institute
- Biosensor device and assembly methods11 Mar 2021US 2021/0071238 A1Queen Mary University of London
- Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer5 Apr 2018US 2018/0092930 A1Janssen Pharmaceutica NV
- Y1 receptor activator for treating an anticancer agent-induced nephrotoxic injury10 Aug 2017US 2017/0224781 A1Kyungpook National University Industry-Academic Cooperation Foundation
Most cited
By later US patents
- Certain alkylene diamine-substituted heterocycles126US 6,506,762 B1Neurogen Corporation · 2003
- Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines47US 6,372,743 B1Neurogen Corporation · 2002
- Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines11US 6,476,038 B1Neurogen Corporation · 2002
- Certain alkylene diamine-substituted heterocycles3US 6,696,445 B2Neurogen Corporation · 2004
- Certain alkylene diamine-substituted heterocycles2US 7,074,929 B2Neurogen Corporation · 2006